Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Open Access
- 30 January 2022
- journal article
- research article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 20 (1), 64-71
- https://doi.org/10.5217/ir.2020.00100
Abstract
Background/Aims: Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects. An optimal maintenance strategy in these patients needs to be established. Methods: A retrospective analysis of maintenance of clinical remission with combination of azathioprine (AZA) and 5-aminosalicylates (5-ASA) in patients with severe steroid refractory UC where IFX (5 mg/kg intravenously at weeks 0, 2, 6) had been used only as an induction therapy was done at 2 centers in India. Primary outcome was the proportion of patients maintaining corticosteroid-free sustained clinical remission (SCR) at the end of study period. Rates of relapse and cost of therapy were also analyzed. Results: Of the 137 patients who received rescue IFX induction therapy, 77 (56.2%) achieved clinical remission (mean age 34.81 +/- 13.32 years, 68.83% males, median follow-up 4 years, range 3 months to 6 years) and were included. Cumulative corticosteroid-free SCR was maintained in 68%, 59%, 42%, and 35% patients at 1, 2, 4, and 6 years respectively. Sixty-seven relapses were observed in 33 patients. Majority of the relapses (45/67, 67.16%) occurred within first 2 years of follow-up. Two relapses were managed with re-induction with IFX, one required colectomy, whereas all other responded to repeat course(s) of corticosteroids. Annual per capita maintenance therapy with 5-ASA and AZA was cheaper by US$ 4,526 compared to maintaining remission with IFX. Conclusions: Clinical remission achieved with IFX induction therapy in severe steroid-refractory UC can be sustained over long time with a combination of AZA and 5-ASA.Keywords
This publication has 32 references indexed in Scilit:
- Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experienceIndian Journal of Gastroenterology, 2013
- Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension StudiesInflammatory Bowel Diseases, 2012
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is StoppedGastroenterology, 2012
- Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab studyAlimentary Pharmacology & Therapeutics, 2010
- A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative ColitisClinical Gastroenterology and Hepatology, 2009
- Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-RegressionClinical Gastroenterology and Hepatology, 2007
- Transcription factor‐mediated molecular mechanisms involved in the functional cross‐talk between cytokines and glucocorticoidsImmunology & Cell Biology, 2001
- Azathioprine: an Update on Clinical Efficacy and Safety in Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999
- Predicting outcome in severe ulcerative colitis.Gut, 1996
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyThe New England Journal of Medicine, 1994